Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.
As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.
Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?
As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.
Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.
To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
Geisinger is aiming to offer DNA sequencing to all of its 1.5 million patients. Members of its precision health team reveal how the initiative developed and share insights gleaned so far, challenges ahead and questions still to be answered.
Receiving payments from industry influenced physicians’ device selection but not patient outcomes, according to researchers who analyzed three years of Open Payment Program data.
A new stem cell-based test may add certainty to efforts to predict whether so-called variants of uncertain significance will contribute to the development of diseases or be harmless.
